Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02061462
Other study ID # EVLP_2013
Secondary ID
Status Recruiting
Phase Phase 1
First received February 11, 2014
Last updated November 25, 2014
Start date October 2014
Est. completion date April 2017

Study information

Verified date November 2014
Source Policlinico Hospital
Contact n/a
Is FDA regulated No
Health authority Italy: Ethics Committee
Study type Interventional

Clinical Trial Summary

The procurement of organs from donors after cardiocirculatory death (DCD) is an accepted strategy to increase organ supply.


Description:

Aim of the investigation: to compare the clinical outcome after transplantation of subjects receiving lungs procured from donors after cardiocirculatory death reconditioned and assessed by EVLP, with that of subjects receiving lungs procured from brain death donors.


Recruitment information / eligibility

Status Recruiting
Enrollment 10
Est. completion date April 2017
Est. primary completion date October 2016
Accepts healthy volunteers No
Gender Both
Age group 15 Years and older
Eligibility Lung donors:

- subjects with brain death according to neurological or cardiocirculatory criteria

- age below 65 yrs

- absence of massive lung contusion, aspiration, pneumonia, sepsis

- absence of infection, malignancy

Recipients:

- subjects to undergo single or bilateral lung transplantation

- informed consent to participate in the study

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic


Related Conditions & MeSH terms


Intervention

Procedure:
EVLP-DCD Group
Events: application of an open lung protective ventilatory strategy (recruitment manoeuvre, low volume-low frequency ventilation-high PEEP) to the DCD donors; procurement of lungs and cold storage on ice; reconditioning/evaluation by EVLP to assess suitability for transplantation; cold storage on ice; transplantation. Endpoints of suitability: oxygenation, respiratory mechanics, pulmonary vascular resistance, chest X-ray, fibrobronchoscopy

Locations

Country Name City State
Italy Fondazione IRCCS a' Granda - Ospedale Maggiore Policlinico Milan

Sponsors (2)

Lead Sponsor Collaborator
Policlinico Hospital San Gerardo Hospital

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Other Bronchiolitis Obliterans Syndrome (BOS) 12 months Yes
Primary 30 Day Mortality and Graft Survival 30 day mortality and graft survival is used as a standard research measure to evaluate post transplant outcome 30 days Yes
Secondary Duration of mechanical ventilation after transplantation 30 days Yes
Secondary ICU length of stay after transplantation 30 days Yes
Secondary Primary Graft Dysfunction 72 hours After Transplantation Primary Graft Dysfunction 72 hours after transplantation definition: grade 3 according to the International Society of Heart and Lung Transplantation classification 72 hours Yes
See also
  Status Clinical Trial Phase
Recruiting NCT03948529 - RevErsing Poor GrAft Function With eLtrombopag After allogeneIc Hematopoietic Cell trAnsplantation Phase 2
Completed NCT03663036 - Arthroscopic Superior Capsular Reconstruction With Fascia Lata Autograft - Survivorship of the Autograft Analysis N/A
Not yet recruiting NCT05855707 - Wharton Jelly Mesenchymal Stromal Cells as GVHD Prophylaxis Phase 1
Recruiting NCT04967391 - Tumescence in HNC Skin Graft Reconstruction Phase 3
Completed NCT01970605 - Silver Graft All Comers Registry
Terminated NCT01564095 - TOP-Study (Tacrolimus Organ Perfusion): Treatment of Ischemia Reperfusion Injury in Marginal Organs With an ex Vivo Tacrolimus Perfusion Phase 2/Phase 3
Terminated NCT00208884 - Terminal Graft Failure N/A
Recruiting NCT04779957 - Evaluation of the Safety of Use of Anti-IL6 Receptor Antibodies to Reduce Allo-sensitization Post Allograft Nephrectomy Phase 2
Terminated NCT04494061 - A Clinical Study to Investigate Interferon Gamma (IFNɣ) Signature in Patients Post HSCT and in Patients With Impaired HSC Proliferation Pre-transplant
Terminated NCT04731298 - Study to Investigate the Pharmacokinetics, Pharmacodynamics and Assess the Efficacy and Safety to Support Dose Selection of Emapalumab in Pre-empting Graft Failure in Patients at High Risk After HSCT. Phase 2
Completed NCT01848249 - Deceased Donor Biomarkers and Recipient Outcomes
Active, not recruiting NCT02556879 - Immunization Anti HLA in the Liver Transplant Recipients (DSATH) N/A
No longer available NCT02026934 - CliniMACS® CD34+ Reagent System for Expanded Access Use N/A
Recruiting NCT00472329 - Fludarabine and 400 CGY Total Body Irradiation for Recipients of HLA-Matched or Mis-Matched Family or Unrelated Donor Hematopoietic Stem Cell Transplants Who Have Rejected Their First Allogeneic Stem Cell Transplant Phase 2
Completed NCT04542954 - Optimized Management of Covid-19 Positive Kidney Transplant Recipients: Single Center Experience From the Middle East
Recruiting NCT03717545 - Second Transplantation for Graft Failure N/A
Recruiting NCT03019809 - A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients Phase 2
Recruiting NCT01631058 - Renal Transplantation in the Elderly - nEverOld Study Phase 4
Completed NCT06340607 - Neohepatic Albumin-Bilirubin Scores on Renal Outcomes in Living-donor Liver Transplantation Recipients
Not yet recruiting NCT04685174 - Intraoperative NIRS of Transplanted Kidney for Prediction of Acute and Sub-acute Injury Phase 3